A 12-Week Phase-IV Evaluation of Safety and Efficacy of Trifarotene Treatment for Facial and Truncal Acne in Indian Subjects Chandrashekar BS, MD; Sushil Tahiliani, MD; Abhishek De, MD; Dyotona Sen, MD NEXT POSTER > POSTER 1

A Narrative Review of Treatment Adherence in Patients With Acne Vulgaris Steven R. Feldman, MD, PhD; Linda Stein Gold, MD; Emil A. Tanghetti, MD; Karol Wroblewski, PharmD; Vivek K. Trivedi, PharmD; Leon H. Kircik, MD < PREVIOUS POSTER NEXT POSTER > POSTER 2

Complete Scalp Hair Regrowth and Predictors of Response in Patients with Alopecia Areata Receiving Ritlecitinib 50 mg up to 3 Years in the ALLEGRO Clinical Trial Program Brett King, Rodney Sinclair, Lidia Rudnicka, Sergio Vañó-Galvan, Bianca Maria Piraccini, Manabu Ohyama, Wenyu Wu, Gianluca Bonfanti, Roger A Edwards, Robert Wolk, Stephen Goodrich, Dalia Wajsbrot, Helen Tran, Alexandre Lejeune < PREVIOUS POSTER NEXT POSTER > POSTER 3

Complete Hair Regrowth in Patients with Alopecia Areata (AA) and ≥25% Scalp Hair Loss Receiving Ritlecitinib up to 3 Years in ALLEGRO-LT Brett King, Rodney Sinclair, Lidia Rudnicka, Sergio Vañó-Galvan, Bianca Maria Piraccini, Manabu Ohyama, Wenyu Wu, Robert Wolk, Stephen Goodrich, Dalia Wajsbrot, Helen Tran, Alexandre Lejeune < PREVIOUS POSTER NEXT POSTER > POSTER 4

Long-Term Efficacy, Complete Scalp Hair Regrowth, and Normal Body Hair and Nails in Patients with Alopecia Areata (AA) Receiving Ritlecitinib 50 mg Once Daily up to 3 Years in the ALLEGRO Clinical Trial Program Brett King, Rodney Sinclair, Lidia Rudnicka, Sergio Vañó-Galvan, Bianca Maria Piraccini, Manabu Ohyama, Wenyu Wu, Robert Wolk, Dalia Wajsbrot, Helen Tran, Alexandre Lejeune < PREVIOUS POSTER NEXT POSTER > POSTER 5

Early Improvement in Scalp Hair Regrowth with Deuruxolitinib in Patients with Severe Alopecia Areata: Pooled Analysis of the THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials Arash Mostaghimi, MD, MPH; Maryanne M. Senna, MD; Brett King, MD, PhD; Natasha A. Mesinkovska, MD, PhD; Heidi Goldstein, MA; Yasmin Mathlin, MD, DNP, DCNP; Kizito Kyeremateng, PharmD; Nicholas Squittieri, MD < PREVIOUS POSTER NEXT POSTER > POSTER 6

Efficacy of Deuruxolitinib Across Subgroups of Patients with Severe Alopecia Areata by Demographic and Baseline Characteristics: Pooled Analysis of the THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials Maryanne M. Senna, MD; Brett King, MD, PhD; Natasha A. Mesinkovska, MD, PhD; Arash Mostaghimi, MD, MPH; Heidi Goldstein, MA; Yasmin Mathlin, MD, DNP, DCNP; Kizito Kyeremateng, PharmD; Nicholas Squittieri, MD < PREVIOUS POSTER NEXT POSTER > POSTER 7

Deuruxolitinib Improves Scalp Hair Regrowth Over Time in Patients with Severe Alopecia Areata: Pooled Analysis of the THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials Natasha A. Mesinkovska, MD, PhD; Arash Mostaghimi, MD, MPH; Maryanne M. Senna, MD; Brett King, MD, PhD; Heidi Goldstein, MA; Yasmin Mathlin, MD, DNP, DCNP; Kizito Kyeremateng, PharmD; Nicholas Squittieri, MD < PREVIOUS POSTER NEXT POSTER > POSTER 8

Efficacy of Deuruxolitinib in Patients with Severe Alopecia Areata by Baseline Nail Involvement: Pooled Post Hoc Analysis of the THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials Natasha A. Mesinkovska, MD, PhD; Brett King, MD, PhD, Arash Mostaghimi, MD, MPH; Maryanne M. Senna, MD; Heidi Goldstein, MA; Yasmin Mathlin, MD, DNP, DCNP; Kizito Kyeremateng, PharmD; Nicholas Squittieri, MD < PREVIOUS POSTER NEXT POSTER > POSTER 9

Efficacy of Deuruxolitinib in Patients with Severe Alopecia Areata by Baseline Eyelash Involvement: Pooled Post Hoc Analysis of the THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials Maryanne M. Senna, MD; Natasha A. Mesinkovska, MD, PhD; Brett King, MD, PhD; Arash Mostaghimi, MD, MPH; Heidi Goldstein, MA; Yasmin Mathlin, MD, DNP, DCNP; Kizito Kyeremateng, PharmD; Nicholas Squittieri, MD < PREVIOUS POSTER NEXT POSTER > POSTER 10

Efficacy of Deuruxolitinib in Patients with Severe Alopecia Areata by Baseline Eyebrow Involvement: Pooled Post Hoc Analysis of the THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials Arash Mostaghimi, MD, MPH; Maryanne M. Senna, MD; Natasha A. Mesinkovska, MD, PhD; Brett King, MD, PhD; Heidi Goldstein, MA; Yasmin Mathlin, MD, DNP, DCNP; Kizito Kyeremateng, PharmD; Nicholas Squittieri, MD < PREVIOUS POSTER NEXT POSTER > POSTER 11

Efficacy of Deuruxolitinib in Patients with Severe Alopecia Areata by Baseline Alopecia Areata Episode Duration: Pooled Analysis of the THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials Authors: Brett King, Jennifer Soung, Christos Tziotzios, Lidia Rudnicka, Pascal Joly, Melinda Gooderham, Rodney Sinclair, Susan D. Anway, Dalia Wajsbrot, Alexandre Lejeune, Samuel H. Zwillich < PREVIOUS POSTER NEXT POSTER > POSTER 12

Long-Term Laboratory Trends in Patients with Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib: 140-Week Results from Measure Up 1 and 2 David G Cotter, Mona Shahriari, Diego Ruiz Dasilva, Erik Domingues, Shanthi Narla, Mark G Kirchhof, Rachel Goldberg, Meerat Oza, Deanne Dilley, Ayman Grada, Alan D Irvine < PREVIOUS POSTER NEXT POSTER > POSTER 13

Asthma Control in Patients with Moderate-To-Severe Atopic Dermatitis and Comorbid Asthma Receiving Lebrikizumab in a Real-World Setting: Interim Data from the AD-LIFE Non-Interventional Study Roland Buhl, Andreas Wollenberg, Thomas Bieber, Ralf Gutzmer, Afra Kempf, Sebastian Diemert, Laura Susok, Diamant Thaçi, Bob Geng, Felix Lauffer < PREVIOUS POSTER NEXT POSTER > POSTER 14

Lebrikizumab Dosed Every 8 Weeks as Maintenance Provides Long-Lasting Response in Patients with Moderate-to-Severe Atopic Dermatitis Jonathan Silverberg, Vivian Laquer, Peter Lio, Kim Papp, Alan Irvine, Andrew Blauvelt, Hany Elmaraghy, Louise DeLuca-Carter, Heidi Crane, Gaia Gallo, Evangeline Pierce, Yuxin Ding7 Amy S. Paller < PREVIOUS POSTER NEXT POSTER > POSTER 15

Lebrikizumab Provides Clinically Meaningful Response in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: ADhope1 Study Primary Results Diamant Thaçi, Alan Irvine, Christian Vestergaard, Christine Bangert, Jan Gutermuth, Helena Agell, Júlia Valls Bancells, Victor Sapena, Ruth Coll, Marjolein de Bruin-Weller < PREVIOUS POSTER NEXT POSTER > POSTER 16

Real-World Effectiveness of Lebrikizumab in Atopic Dermatitis Patients at 6 Months: Results from the PPD™ CorEvitas™ AD Registry in the United States and Canada Eric L. Simpson, Vimal H. Prajapati, William McCann, Evangeline Pierce, Alvin Li, Chien-Wen J. Choi, Bryce J. Wiley, Zach Dawson, Elsa Inman, Kayla Callahan, Jonathan I. Silverberg < PREVIOUS POSTER NEXT POSTER > POSTER 17

Efficacy and Safety of Lebrikizumab is Maintained up to 4 Years in Patients With Moderate-to-Severe Atopic Dermatitis: First year of ADlong Long-Term Extension Trial Stephan Weidinger, Alan Irvine, Diamant Thaçi, Jacek C Szepietowski, Tilo Biedermann, Helena Agell, Yanislav Mihaylov, Belchin Kostov, Ruth Coll, William Romero, Kristian Reich < PREVIOUS POSTER NEXT POSTER > POSTER 18

Flare-Free Disease Control Up to 3 Years Following Lebrikizumab Treatment in Atopic Dermatitis Patients Achieving 16-Week Response: A Post-Hoc Analysis of the ADjoin Study Joseph Merola, Leon Kircik, Sebastien Barbarot, Jose Manuel Carrascosa, Stephan Weidinger, Peter Lio, Francis Corrado, Gaia Gallo, Yuxin Ding, Yi Li, Helena Agell, Jonathan I Silverberg < PREVIOUS POSTER NEXT POSTER > POSTER 19

Improvement in Time to Itch Relief After Use of Both a Lotion and Cream for Eczema Patients Thu Q. Nguyen, PhD; Sindhu Garimella MS; Christine Emesiani, PharmD; Matthew Meckfessel, PhD < PREVIOUS POSTER NEXT POSTER > POSTER 20

Long-Term Disease Control and Safety With Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis Following Failure of Prior Topical Therapies: Results From the TRuE-AD4 Phase 3b Study Andreas Wollenberg, MD, PhD, H. Chih-ho Hong, MD, Elaine Agius, MD, PhD, Nina Magnolo, MD, Ketty Peris, MD, PhD, Eingun James Song, MD, Sébastien Barbarot, MD, PhD, Konstantin Popovic, PhD, Brett Angel, MD, Qian Li, PhD, José Manuel Carrascosa, MD, PhD < PREVIOUS POSTER NEXT POSTER >

Tralokinumab versus Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis with Hand Involvement: A Matching-Adjusted Indirect Comparison April Armstrong, Leon Kircik, Andrei Metelitsa, Richard B. Warren, Adrian Rodriguez, Sebastian Volc, Naiem Issa, Raj Chovatiya, Rie von Eyben, Teodora Festini, Pierre Johansen, Benjamin Ehst < PREVIOUS POSTER NEXT POSTER > POSTER 22

Tralokinumab Treatment in Patients with Atopic Dermatitis and Moderate-to-Severe Hand Involvement: Results from the 32-Week Phase 3b ADHAND Trial Benjamin Ehst,1 Richard B. Warren,H. Chih-ho Hong, Dong Hun Lee, Andrei Metelitsa, Sebastian Volc, Marie Tauber, Farzaneh Safavimanesh, Ann-Marie Tindberg, Linda Stein-Gold < PREVIOUS POSTER NEXT POSTER > POSTER 23

Real-World Effectiveness and Tolerability of Tralokinumab in a Patient with Severe Atopic Dermatitis Refractory to Dupilumab and Janus Kinase Inhibitor Treatment Marley Cutrona, Alexandra K. Golant < PREVIOUS POSTER NEXT POSTER > POSTER 24